Taysha Gene Therapies (TSHA) has wrapped up FY 2025 with Q4 revenue of US$5.5 million and a basic EPS loss of US$0.08, alongside a full year trailing revenue base of US$9.8 million and a trailing EPS loss of US$0.34 that keeps profitability firmly out of reach for now. Over recent quarters, the company has seen revenue move between US$0 and US$5.5 million while quarterly basic EPS losses ranged from about US$0.08 to US$0.10. This sets a clear picture of a business still in heavy investment mode. For investors, the focus this season is on how that revenue base and persistent net losses shape the margin profile and what that implies for the balance between risk and potential growth.

See our full analysis for Taysha Gene Therapies.

With the latest numbers on the table, the next step is to set these results against the widely held narratives around Taysha Gene Therapies to see which views hold up and which start to look out of line.

LTM loss of US$109 million keeps profitability distant

• Over the last twelve months, Taysha reported total revenue of US$9.8 million against a net loss of US$109.0 million and a trailing basic EPS loss of US$0.34, so the income statement is still heavily in the red.
• Bulls often point to high expected revenue growth and the TSHA-102 program as the core of their thesis, yet
  • analysts are assuming revenue could grow at around 59.1% per year while the company is not expected to be profitable over the next three years, which leaves a wide gap between top line potential and current earnings power, and
  • bullish scenarios that look for earnings of about US$24.6 million by 2028 start from today’s US$99.9 million loss, so a very large swing in profitability would need to occur for that view to play out.

Bulls argue that TSHA-102 could transform these heavy losses into meaningful earnings if trials and commercialization go to plan, and you can see how that story is framed in more detail in the 🐂 Taysha Gene Therapies Bull Case

Share price at US$4.56 versus higher models and targets

• The current share price of US$4.56 sits far below a DCF fair value of about US$98.55 and also below an analyst price target of US$11.29, so models that lean on long term cash flows or consensus assumptions imply a large gap to where the stock trades today.
• What stands out in the bearish narrative is how much optimism is already baked into those same models, because
  • the cautious camp still assumes revenue growth of roughly 145.5% a year for several years and a future earnings figure of about US$15.2 million, which is a big shift from the current US$99.9 million loss, and
  • to reach that bearish price target, the shares would need to trade on a P/E multiple around 190x those projected earnings, which is far higher than the 21.5x cited for the broader US biotech industry.

Skeptics point out that even cautious valuation setups rely on very optimistic growth and profitability swings, so it is worth reading how that case is built in the 🐻 Taysha Gene Therapies Bear Case

Rich 5.1x P/B and recent dilution raise risk questions

• Taysha trades on a P/B of 5.1x compared with a peer average of 4.1x and a US biotechs industry average of 2.5x, while shareholders have also faced substantial dilution over the past year and recent insider selling over the last three months.
• Consensus commentary highlights strong forecast revenue growth and the TSHA-102 pipeline as reasons some investors accept that richer multiple, yet
  • the company is still loss making with a trailing net loss of around US$109.0 million and is not forecast to achieve profitability within three years, and
  • major dilution and insider selling sit alongside these loss figures, which means any future upside from revenue growth could be shared across a growing share count and may not fully offset capital structure risks.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Taysha Gene Therapies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of heavy losses, rich multiples and ambitious expectations, sentiment around Taysha is clearly split. Move quickly, review the full data set and form your own stance by weighing its 2 key rewards and 3 important warning signs

See What Else Is Out There

Taysha is still posting heavy losses, carries a rich 5.1x P/B multiple and has seen substantial dilution, so balance sheet risk remains front and center.

If those risks feel a bit too high for your comfort, shift your attention to companies with steadier profiles by scanning the 72 resilient stocks with low risk scores today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.